Four monoclonal antibodies (mAbs) gained approval in 2009 ... marketed in the US by J&J and in Europe by Merck of Whitehouse Station, New Jersey, following its acquisition of Kenilworth, New ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It also profiles the leading makers of antibody drugs, such as AbbVie and Amgen. The report focuses on how monoclonal ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Unlike deals made decades ago related to mAbs, larger pharmaceutical companies are not waiting for the cell and gene therapy sector to become well established before pursuing partnerships or M&A ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

Mammalian derived proteins are essential in the production of monoclonal antibodies (MABs), clotting factors, and hormones, ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

It looks like there's no data for these filter options. Maybe you'll be interested in these options instead.